Tanvir Khaliq
Assistant Professor
Biography
Tanvir Khaliq, Ph.D., is a medicinal chemist with expertise in drug design and development for the protozoan parasitic diseases leishmaniasis and malaria, as well as opioid pain and drug abuse.
After receiving his Ph.D. in medicinal chemistry, Khaliq was a postdoctoral fellow at the University of Washington and the University of Kansas, where he rose through the ranks as an associate researcher prior to moving to the University of Florida as a senior chemist in medicinal chemistry.
Khaliq has discovered novel natural products and designed and synthesized their analogs that are orally active against the drug-resistant strains of leishmaniasis and malaria. He has developed a cost-effective and reliable screening method for newborn screening of inborn errors of metabolism. These methods are being used in newborn screening laboratories across the United States as well as abroad. He has characterized preclinical pharmacokinetic properties of structurally novel and orally bioavailable macrocyclic tetrapeptides that are active at the kappa opioid receptors to facilitate their potential development as treatments for pain and drug abuse.
Khaliq teaches medicinal chemistry in the professional pharmacy and the pharmaceutical sciences graduate programs. He is a member of the American Chemical Society in the Divisions of Organic, Medicinal and Biological Chemistry and the Rho Chi Honor Society.
After receiving his Ph.D. in medicinal chemistry, Khaliq was a postdoctoral fellow at the University of Washington and the University of Kansas, where he rose through the ranks as an associate researcher prior to moving to the University of Florida as a senior chemist in medicinal chemistry.
Khaliq has discovered novel natural products and designed and synthesized their analogs that are orally active against the drug-resistant strains of leishmaniasis and malaria. He has developed a cost-effective and reliable screening method for newborn screening of inborn errors of metabolism. These methods are being used in newborn screening laboratories across the United States as well as abroad. He has characterized preclinical pharmacokinetic properties of structurally novel and orally bioavailable macrocyclic tetrapeptides that are active at the kappa opioid receptors to facilitate their potential development as treatments for pain and drug abuse.
Khaliq teaches medicinal chemistry in the professional pharmacy and the pharmaceutical sciences graduate programs. He is a member of the American Chemical Society in the Divisions of Organic, Medicinal and Biological Chemistry and the Rho Chi Honor Society.
Education
- Teaching certificate in pharmacy | University of Florida
- Ph.D. in medicinal chemistry | Central Drug ĢƵ Institute
- Postdoctoral in medical chemistry | University of Kansas, University of Florida
Academic and Professional Experience
Academic Interests
- Parasitic diseases
- Drug discovery
- Medicinal chemistry
- Organic synthesis
- Pharmacokinetics
Academic Responsibilities
- PHA 340 – Medicinal Chemistry I
- Organic functional groups and their relevance to physicochemical and ADME properties
- Heterocycles
- Stereochemical principles
- ADME (absorption, distribution, metabolism and excretion)
- PHA 341 – Medical Chemistry II
- CNS depressants and stimulants
- Local anesthetics
- Opioid analgesics and antagonists
- Nonsteroidal anti-inflammatory drugs
- PHA 721 – Advanced Concepts in Medicinal Chemistry
- Drug design
- Enzyme inhibition and inactivation
Committees and Professional Memberships
Committees
- Faculty Development Committee
- Pharm.D. Accreditation Committee
- Curricular Progression and Variation Committee
- Scholarship and Awards Committee
Professional Memberships
- American Chemical Society, Divisions of Organic, Medicinal and Biological Chemistry
- Rho Chi Honor Society
ĢƵ and Scholarly Work
Areas of ĢƵ
Work in Khaliq’s laboratory is primarily focused on antiparasite drug discovery and development. ĢƵ focuses on the rational design and synthesis of novel analogs of natural products as antiparasite agents for their potential development as treatments against leishmaniasis and trypanosomiasis, which have led to a devastating impact on public health in the developing world. A major emphasis is on developing cost-effective and orally active molecules that are also active against the drug-resistant strains.
One of the current projects in his laboratory is exploring the structure-activity relationships of a structurally novel and an orally active quinazoline alkaloid to optimize its antiparasite activity against the clinically relevant intracellular leishmania parasite. The compounds are studied both in vitro against the intracellular parasites and in vivo in murine visceral leishmaniasis model. Selected compounds are evaluated for their pharmacokinetic properties and against the clinically resistant strains to facilitate their potential development. The laboratory utilizes both classical medicinal chemistry and structure- and ligand-guided approaches to design novel compounds and uses efficient synthetic procedures for the rapid generation of the rationally designed molecules.
Awards and Honors
- Medicinal chemistry (MEDI) award, American Chemical Society
- Travel grant by the International Narcotic ĢƵ Committee
- Junior ĢƵ Fellowship
- Senior ĢƵ Fellowship
Grants
- Structure-activity relationships of peganine for antileishmanial activity. South Dakota Board of Regents Competitive ĢƵ Grant FY23, Status: Recommended for funding.
- Design, synthesis and biological evaluation of novel analogs of quinazoline alkaloid-based natural products for the protozoan parasitic diseases leishmaniasis and trypanosomiasis. ĢƵ 3D (Drug, Disease and Delivery) ĢƵ Center, Status: Startup funding.
- Recombinant neurotrophic factor for cognitive deficits in Alzheimer’s disease. National Institute on Aging, Status: Pending.
Patents
- Duffey, T.A.; Khaliq, T.; Gelb, M.H.; Scott, R.C.; Turecek, F.; Wolfe, B.J. Mass spectrometric compositions and methods for lysosomal storage disease screening WO2012027612A1, March 1, 2012.
Publications
- Khaliq, T.; Joshi, A.; Senadheera, S.N.; Lunte, S.M.; Aldrich, J.V. Preclinical pharmacokinetic properties of the novel macrocyclic peptide kappa opioid receptor ligands CJ-15,208 and [D-Trp] CJ-15,208. (In-preparation)
- Khaliq, T.; Brice‐Tutt, A.C.; Stacy, H.M.; Coleman, J.S.; McLaughlin, J.P.; Aldrich, J.V. Preclinical evaluation of the orally bioavailable macrocyclic mixed opioid agonist/antagonist tetrapeptide cyclo. (In-preparation)
- Khaliq, T.; Aldrich, J.V. Structure-metabolism relationships of novel macrocyclic peptide kappa opioid receptor ligands. (In-preparation)
- Brice‐Tutt, A.C.; Senadheera, S.N.; Ganno, M.L.; Eans, S.O.; Khaliq, T.; Murray, T.F.; McLaughlin, J.P.; Aldrich, J.V. Phenylalanine stereoisomers of CJ‐15,208 and [D‐Trp]CJ‐15,208 exhibit distinctly different opioid activity profiles. Molecules 2020, 25, 3,999.
- Khaliq, T.; Williams, T.D.; Senadheera, S.N.; Aldrich, J.V. Development of robust, sensitive and selective liquid chromatography-tandem mass spectrometry assay for the quantification of the novel macrocyclic peptide kappa opioid receptor antagonist D-Trp [CJ 15,208] in plasma and application to a pharmacokinetic study. Journal of Chromatography B 2016, 1028, 11-15.
- Shivahare, R.; Korthikunta, V.; Chandasana, H.; Suthar, M.K.; Agnihotri, P.; Vishwakarma, P.; Chaitanya, T.K.; Kancharla P.R.; Khaliq, T.; Gupta, S.; Bhatta, R.S.; Pratap, V.J.; Saxena, J.K.; Gupta, S.; Narender, T. Synthesis, structure-activity relationships and biological studies of chromenochalcones as potential antileishmanial agents. Journal of Medicinal Chemistry 2014, 57, 3,342–3,357. (Currently among the most read articles)
- Narender, T.; Korthikunta, V.; Gupta, S.; Kancharla P.R.; Khaliq, T.; Soni, A.; Srivastava, R.K.; Srivastava, K.; Puri, S.K.; Siva Rama Raju, K.; Wahajuddin, Sijwali, P.S.; Kumar, V.; Siddiqi, M.I. Synthesis and insight into the structure-activity relationships of chalcones as antimalarial agents. Journal of Medicinal Chemistry 2013, 56, 31-45. (Highly read article of 2012)
- Singh, V.K.; Mishra, V.; Tiwari, S.; Khaliq, T.; Barthwal, M.K.; Pandey, H.P.; Palit, G.; Narender, T. Antisecretory and cytoprotective effects of peganine hydrochloride isolated from the seeds of Peganum harmala on gastric ulcers. Phytomedicine, 2013, 20, 1,180-1,185.
- Singh, A.B.; Khaliq, T.; Chaturvedi, J.P.; Narender, T.; Srivastava, A.K. Antidiabetic and antioxidative effects of 4-hydroxypipecolic acid in C57BL/KsJ-db/db mice. Human and Experimental Toxicology 2012, 31, 57-65.
- Khaliq, T.; Sadilek, M.; Scott, R.C.; Turecek, F.; Gelb, M.H. Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: Application to screening newborns for mucopolysaccharidosis IVA (morquio A). Clinical Chemistry 2011, 57, 128-131.
- Duffey, T.A.; Khaliq, T.; Scott, R.C.; Turecek, F.; Gelb, M.H. Design and synthesis of reagents for newborn screening of maroteaux-Lamy and morquio A syndromes. Bioorganic and Medicinal Chemistry Letters 2010, 20, 5,994-5,996.
- Duffey, T.A.; Gelb, M.H.; Scott, R.C.; Turecek, F.; Khaliq, T. Newborn screening for lysosomal storage disorders: Tandem mass spectrometry to quantitate enzymatic activity. Molecular Genetics and Metabolism 2010, 99, S16.
- Khaliq, T.; Misra, P.; Gupta, S.; Kancharla P.R.; Kant, R.; Maulik, P.R.; Dube, A.; Narender, T. Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorganic and Medicinal Chemistry Letters 2009, 19, 2,585-2,586.
- Narender, T.; Khaliq, T.; Singh, A.B.; Joshi, M.D.; Mishra, P.; Chaturvedi, J.P.; Srivastava, A.K.; Maurya, R.; Agarwal, S.C. Synthesis of α-amyrin derivatives and their in vivo antihyperglycemic activity. European Journal of Medicinal Chemistry 2009, 44, 1,215-1,222.
- Misra, P.; Khaliq, T.; Dixit, A.; Sengupta, S.; Samant, M.; Kumari, S.; Kumar, A.; Kushawaha, P.; Majumder, H.; Saxena, A.; Narender, T.; Dube, A. Antileishmanial activity mediated by apoptosis and structure based target study of peganine hydrochloride dihydrate: An approach for rational drug designing. Journal of Antimicrobial Chemotherapy 2008, 62, 998-1,002.
- Narender, T.; Khaliq, T.; Srivastava, M.N. Naturally occurring 1, 1'-trimethylenebisuracil from the marine sea hare. Dolabella auricularia. Natural Product Communications 2007, 2, 7,173.
- Narender, T.; Khaliq, T. A new triterpenoid from Peganum harmala. Natural Product Communications 2007, 2, 1,079-1,081.
- Narender, T.; Sahu, S.; Tiwari, P.; Kancharla P.R.; Khaliq, T.; Prathipati, P.; Puri, A.; Srivastava, A.K.; Chander, R.; Agarwal, S.C.; Raj, K. Antihyperglycemic and antidyslipidemic agent from Aegle marmelos. Bioorganic and Medicinal Chemistry Letters 2007, 17, 1,808-1,811.
- Roy, A.D.; Kumar, R.; Gupta, P.; Khaliq, T.; Narender, T.; Agarwal, V.L.; Roy, R. Xyloccensin X and Y, two new limonoids from Xylocarpus molluccensis: NMR investigation in mixture. Magnetic Resonance in Chemistry 2006, 44, 1,054-1,057.
- Narender, T.; Khaliq, T.; Puri, A.; Chander, R. Antidyslipidemic activity of furano-flavonoids isolated from Indigofera tinctoria. Bioorganic and Medicinal Chemistry Letters 2006, 16, 3,411-3,414.
- Narender, T.; Puri, A.; Shweta; Khaliq, T.; Saxena, R.; Bhatia, G.; Chandra, R. 4-Hydroxyisoleucine an unusual amino acid as antidyslipidemic and antihyperglycemic agent. Bioorganic and Medicinal Chemistry Letters 2006, 16, 293-296.
- Narender, T.; Shweta; Khaliq, T.; Rao, M.S.; Srivastava, K.; Puri, S.K. Prenylated chalcones isolated from Crotalaria genus inhibits in vitro growth of the human malaria parasite Plasmodium falciparum. Bioorganic and Medicinal Chemistry Letters 2005, 15, 2,453-2,455.
- Narender, T.; Khaliq, T.; Shweta; Nishi; Goyal, N.; Gupta, S. Synthesis of chromenochalcones and evaluation of their in vitro antileishmanial activity. Bioorganic and Medicinal Chemistry Letters. 2005, 13, 6,543-6,550.
